Nicola L. Brice

Nicola L. Brice

Auto-generated profile, based on publicly available information

Nicola L. Brice

Cerevance, United Kingdom

Research Focus & Metrics

Academic Career Length

8Years (2019-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 June 2021 in The Journal of Pharmacology and Experimental Therapeutics
Verified
Journal Article
Closed access
PDF file
NBNicola L. Brice
Nicola L. Brice
HSHans H. Schiffer
Hans H. Schiffer
HMHolger Monenschein
Holger Monenschein
VMVictoria J. Mulligan
Victoria J. Mulligan
KPKeith Page
Keith Page
MCMark B. Carlton
Mark B. Carlton
GPR6 is an orphan GPCR that has enriched expression in the striatopallidal, indirect pathway, medium spiny neurons of the striatum. This pathway is greatly impacted by the loss of the nigro-striatal dopaminergic neurons in Parkinson9s disease and modulating this neurocircuitry can be therapeutically beneficial. In this study we describe the in vitro and in vivo pharmacological characterization of CVN424, a highly potent and selective small molecule inverse agonist for GPR6 which is currently undergoing clinical evaluation. CVN424 is brain penetrant and shows dose dependent receptor occupancy that attained brain RO50 at plasma concentrations of 6.0 ng/ml and 7.4 ng/ml in mice and rats, respectively. Oral administration of CVN424 dose dependently increases locomotor activity and reverses haloperidol-induced catalepsy. Furthermore, CVN424 restored mobility in bilateral 6-OHDA lesion model of Parkinson9s disease. The presence and localization of GPR6 in medium spiny neurons of striatum postmortem samples from both non-demented control and Parkinson9s disease patients was confirmed at the level of both RNA (using NETSseq) and protein. This body of work demonstrates that CVN424 is a potent, orally active and brain penetrant GPR6 inverse agonist which is effective in pre-clinical models and is a potential therapeutic for improving motor function in patients with Parkinson9s disease. Significance Statement CVN424 represents a non-dopaminergic novel drug for potential use in patients with Parkinson’s disease.

2 February 2022 in The Journal of Pharmacology and Experimental Therapeutics
Verified
Journal Article
Open access
PDF file
DMDavid H. Margolin
David H. Margolin
NBNicola L. Brice
Nicola L. Brice
ADAntonia M. Davidson
Antonia M. Davidson
KMKim L. Matthews
Kim L. Matthews
MCMark B.L. Carlton
Mark B.L. Carlton
CVN424 is a novel small molecule and first-in-class candidate therapeutic to selectively modulate GPR6, an orphan G-protein coupled receptor. Expression of GPR6 is largely confined to the subset of striatal projection neurons that give rise to the indirect (striatopallidal) pathway, important in the control of movement. CVN424 improves motor function in preclinical animal models of Parkinson9s disease. Here we report results of a phase 1, first-in-human study investigating the safety, tolerability, and pharmacokinetics of CVN424 in healthy volunteers. The study (NCT03657030) was randomized, double-blind, and placebo controlled. CVN424 was orally administered in ascending doses to successive cohorts as inpatients in a clinical research unit. Single doses ranged from 1 mg to 225 mg, and repeated (7 day) daily doses were 25 mg, 75 mg, or 150 mg. CVN424 peak plasma concentrations were reached within 2h post-dose in the fasted state and increased with increasing dose. Dosing after a standardized high-fat meal reduced and delayed the peak plasma concentration but total plasma exposure was similar. Mean terminal half-life ranged from 30h to 41h. CVN424 was generally well tolerated: no serious or severe adverse effects were observed, and there were no clinically significant changes in vital signs or laboratory parameters. We conclude that CVN424, a nondopaminergic compound that modulates a novel therapeutic target, was safe and well tolerated. A phase 2 study in patients with Parkinson9s disease is underway. Significance Statement This is the first-in-human clinical study of a first-in-class candidate therapeutic. CVN424 modulates a novel drug target, GPR6, which is selectively expressed in a pathway in the brain that has been implicated in the motor dysfunction of patients with Parkinson’s disease. This study paves the way for investigating this novel mechanism of action in patients with Parkinson’s disease.

18 October 2024 in eClinicalMedicine
Verified
Journal Article
Open access
NBNicola L. Brice
Nicola L. Brice
MCMark Carlton
Mark Carlton
DMDavid H. Margolin
David H. Margolin
MBMartin Bexon
Martin Bexon
KMKim L. Matthews
Kim L. Matthews
KKKarl Kieburtz
Karl Kieburtz

30 January 2024 in Bioorganic & Medicinal Chemistry Letters
Verified
Journal Article
Open access
AGAngela Glen
Angela Glen
RBRoland W. Bürli
Roland W. Bürli
DLDavid Livermore
David Livermore
WBWilliam Buffham
William Buffham
SMStephanie Merison
Stephanie Merison
NBNicola L. Brice
Nicola L. Brice
Modulators of orexin receptors are being developed for neurological illnesses such as sleep disorders, addictive behaviours and other psychiatric diseases. We herein describe the discovery of CVN766, a potent orexin 1 receptor antagonist that has greater than 1000-fold selectivity for the orexin 1 receptor over the orexin 2 receptor and demonstrates low off target hits in a diversity screen. In agreement with its in vitro ADME data, CVN766 demonstrated moderate in vivo clearance in rodents and displayed good brain permeability and target occupancy. This drug candidate is currently being investigated in clinical trials for schizophrenia and related psychiatric conditions.

2 February 2022 in Bioorganic & Medicinal Chemistry Letters
Verified
Journal Article
Closed access
RBRussell Burley
Russell Burley
RHRichard C. Hewer
Richard C. Hewer
MTMartin Teall
Martin Teall
LDLouise Dickson
Louise Dickson
BOBernardino Ossola
Bernardino Ossola
RBRoland W. Bürli
Roland W. Bürli

1 May 2021 in Biological Psychiatry
Verified
Journal Article
Closed access
PDF file
NBNicola Brice
Nicola Brice
LDLee A. Dawson
Lee A. Dawson
DMDavid H. Margolin
David H. Margolin
HSHans H. Schiffer
Hans H. Schiffer
HMHolger Monenschein
Holger Monenschein
MCMark Carlton
Mark Carlton